This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Prosensa To Participate At Upcoming Investor Conferences

Leiden, The Netherlands, Jan. 31, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA) announced today that it is schedule to participate at the following investor conferences in  February.
  • 16 th Annual BIO CEO & Investor Conference, Monday, February 10, 2014
  • Corporate Presentation: 9:30 a.m. Eastern Time (webcast available)
  • Panel Participation: 2:00 p.m. Eastern Time (no webcast available)
  • Leerink Partners Global Healthcare Conference 2014,Thursday, February 13, 2014
  • Fireside Chat: 11:35 a.m. Eastern Time (webcast available)
  • Canaccord Genuity Orphan Drug One-on-One Day, Monday, February 24, 2014   
  • 2014 Citi Healthcare Conference, Tuesday, February 25, 2014
  • Panel Participation, 9:40 a.m. Eastern Time (no webcast available)

Live webcasts where available can be accessed through the Investors & Media section of the Prosensa corporate website at http://ir.prosensa.eu/events.cfm and will be archived for 90 days.

About Prosensa Holding N.V.

Prosensa (NASDAQ: RNA) is a Dutch biotechnology company engaged in the discovery and development of RNA-modulating therapeutics for the treatment of genetic disorders. Its primary focus is on rare neuromuscular and neurodegenerative disorders with a large unmet medical need, including Duchenne muscular dystrophy, myotonic dystrophy and Huntington's disease.  www.prosensa.com
CONTACT: Prosensa Holding N.V.
         Celia Economides, Senior Director IR & Corporate Communications
         Phone: +1 917 941 9059
         Email: c.economides@prosensa.nl

Prosensa Holding B.V. Logo

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 16,088.72 -286.04 -1.75%
S&P 500 1,919.05 -32.08 -1.64%
NASDAQ 4,678.8680 -54.6290 -1.15%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs